ZEAL stock news today

Zealand Pharma secures European approval for its drug Zeydovio (glepaglutide)

Regulators in Europe have cleared Zealand Pharma's medicine Zeydovio, also called glepaglutide, for sale. This lets the company start selling the treatment across European countries.

Zealand Pharma receives EU marketing authorization for Zeydovio in short bowel syndrome

The European Commission has approved Zeydovio, a long-acting next-generation GLP-2 analog from Zealand Pharma, for treating adults with short bowel syndrome.

Zealand Pharma restarts glepaglutide partnering discussions, CFO says

Zealand Pharma has begun again its search for a collaborator on glepaglutide, per the finance chief. The company is talking with possible partners about the drug.

Zealand Pharma posts financial results for 2026 period ending in September

Zealand Pharma published its financial results for the year-to-date period through September 2026. The report covers the company's performance during those months.

Zealand Pharma reports positive Phase 1 topline results for ZP9830

Zealand Pharma said its Phase 1 trial of ZP9830 produced positive topline results. The trial is an early-stage study of the drug candidate.

What is the latest news on ZEAL?

Nov 13, 2026: Zealand Pharma secures European approval for its drug Zeydovio (glepaglutide) (Fiscal.ai) · Nov 13, 2026: Zealand Pharma receives EU marketing authorization for Zeydovio in short bowel syndrome (Benzinga) · Nov 12, 2026: Zealand Pharma restarts glepaglutide partnering discussions, CFO says (Fiscal.ai)